Fabry disease (FD) Program in Pharmaceutical Benefits Scheme (PBS) 012-24080524
Expand allThis document outlines details of PBS-subsidised migalastat and pegunigalsidase alfa for patients with Fabry disease (FD).
FD and listing dates
FD is a rare genetic disorder where the deficiency or absence of an enzyme that breaks down a certain type of fat results:
- in a build-up of that fat in many parts of the body, and
- causes a range of symptoms
Listing dates:
- migalastat - 1 September 2024
- pegunigalsidase alfa - 1 August 2026
See Written Authority Required Drugs for more details.
Enquiries
Transfer enquiries about prescription arrangements to PBS Complex Drugs Programs and choose the option relevant to the condition treated.
The Resources page contains:
- application forms
- contact details
- FAQs from Service Officers
- restriction and item codes
- Services Australia website link
Related links
Online Pharmaceutical Benefits Scheme (PBS) Authorities system (OPA system)
Processing an existing Authority request in the Pharmaceutical Benefits Scheme (PBS)
Processing and National Demand Allocation (PaNDA)
Processing Complex Authority Required Listings
Processing Delayed Assessment requests in the Pharmaceutical Benefits Scheme (PBS)
Processing new Authority requests in the Pharmaceutical Benefits Scheme (PBS)